The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
 
Daniel Olson
No Relationships to Disclose
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Actym Therapeutics; Aduro Biotech; Akrevia Therapeutics; Alphamab; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Benevir; Bristol-Myers Squibb; Compugen; Eisai; EMD Serono; IDEAYA Biosciences; Immunocore; Incyte; Janssen; Jounce Therapeutics; Leap Therapeutics; Mavu Pharmaceutical; Merck; Mersana; Novartis; Partner Therapeutics; Reflexion Medical; Spring Bank; Synlogic; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Akrevia Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Immunocore; Janssen; Jounce Therapeutics; Merck; Mersana; Novartis; Reflexion Medical
 
Andrew Stewart Poklepovic
Consulting or Advisory Role - Castle Biosciences; Merck; Novartis
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Merck
 
Madhuri Bajaj
No Relationships to Disclose
 
Emily Higgs
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Research Funding - Lilly (I)
Patents, Royalties, Other Intellectual Property - Jeffrey D. Helterbrand, Richard E. Higgs, Phillip W. Iversen, Automatic Contextual Segmentation for Imaging Bones for Osteoporosis Therapies (Granted 1 Feb 2000, U.S. Patent 6,021,213). Raymond E. Kaiser, Richard E. Higgs, Randall K. Julian Jr., System an (I)
Travel, Accommodations, Expenses - Lilly (I)
 
Timothy C. Carll
No Relationships to Disclose
 
Brian Labadie
No Relationships to Disclose
 
Thomas Krausz
No Relationships to Disclose
 
Yuanyuan Zha
No Relationships to Disclose
 
Theodore Karrison
No Relationships to Disclose
 
Jose Lutzky
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Array BioPharma; Novartis; Regeneron
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Elios Pharmaceutical (Inst); Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Sigrun Hallmeyer
Employment - Advocate Health Care; Oncology Specialists
Leadership - Advocate lutheran general hospital; Advocate Lutheran General Hospital; Advocate lutheran general hospital; Advocate lutheran general hospital; Advocate lutheran general hospital; Oncology Specialists
Honoraria - Array BioPharma; Bristol-Myers Squibb; Immunomedics; Pfizer
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Cardinal Health; Immunomedics; Karyo Biologics; R Pharma
Speakers' Bureau - Bristol-Myers Squibb; Pfizer
Research Funding - Russell Research (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Cardinal Health
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Bruce Brockstein
Consulting or Advisory Role - Blueprint Medicines; Merck
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate. Author and Editorial dutues
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Merck/Schering Plough; Novartis; Pfizer; Polynoma; Regeneron; Replimune
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Polynoma; Replimune
 
Zeynep Eroglu
Consulting or Advisory Role - Array BioPharma; Regeneron; Sun Pharma
Research Funding - Novartis (Inst)
 
Thomas Gajewski
Stock and Other Ownership Interests - Evelo Therapeutics; Five Prime Therapeutics; Jounce Therapeutics
Consulting or Advisory Role - Abbvie; Adaptimmune; Aduro Biotech; Bayer; FOGPharma; Jounce Therapeutics; Merck; Roche/Genentech
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Licensing to Aduro (Inst); Licensing to BMS (Inst); Licensing to Evelo (Inst)
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix
Honoraria - Bristol-Myers Squibb; Sanofi
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Incyte; Merck; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)